Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | CCR8 | P51685 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14305744 | 0.85 | KCNH2 (0.46) | KCNH2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL14306289 | 0.83 | KCNH2 (0.53) | KCNH2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL681576 | 0.83 | KCNH2 (0.49) | KCNH2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL14524676 | 0.82 | KCNH2 (0.43) | KCNH2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL4752742 | 0.82 | PPARG (0.41) | KCNH2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL4750814 | 0.82 | PPARG (0.41) | KCNH2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL6194712 | 0.80 | KCNH2 (0.47) | KCNH2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL14279078 | 0.80 | HRH3 (0.44) | KCNH2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL14499024 | 0.78 | PPARG (0.41) | KCNH2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL14498992 | 0.78 | PPARG (0.39) | KCNH2GABRA1GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063760-A1 | Sodium channel modulatiors | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-04-01 | — | — | US | claimed |
| US-20030065013-A1 | Sodium channel modulators | THERAVANCE BIOPHARMA R&D IP, LLC | 2003-04-03 | — | — | US | claimed |
| WO-2002057215-A2 | SODIUM CHANNEL MODULATORS | THERAVANCE, INC. (US) | 2002-07-25 | — | — | WO | claimed |
| US-7226950-B2 | Sodium channel modulators | THERAVANCE, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-20060276467-A1 | An aromatic-oxy-alkyleneamine derivative, useful for treating neuropathic pain | THERAVANCE BIOPHARMA R&D IP, LLC | 2006-12-07 | — | — | US | disclosed |
| US-7132422-B2 | Sodium channel modulators | THERAVANCE, INC. (US) | 2006-11-07 | — | — | US | disclosed |
| US-20050130966-A1 | Sodium channel modulators | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-06-16 | — | — | US | disclosed |
| US-6872741-B2 | Sodium channel modulators | THERAVANCE, INC. (US) | 2005-03-29 | — | — | US | disclosed |
| US-20040063760-A1 | Sodium channel modulatiors | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-04-01 | — | — | US | disclosed |
| US-6646012-B2 | Central nervous system analgesic; hypotensive agents; antiarrhythmia agents; antidiabetic agents | THERAVANCE, INC. | 2003-11-11 | — | — | US | disclosed |
| US-20030065013-A1 | Sodium channel modulators | THERAVANCE BIOPHARMA R&D IP, LLC | 2003-04-03 | — | — | US | disclosed |
| WO-2002057215-A2 | SODIUM CHANNEL MODULATORS | THERAVANCE, INC. (US) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130966-A1 | Sodium channel modulators | SCN10A, SCN5A, SCN1A | KCNH2 83/4885GABRA1 456/4885GABRG2 445/4885 |
| US-20060276467-A1 | An aromatic-oxy-alkyleneamine derivative, useful for treating neuropathic pain | TRPV1, TRPA1, OPRL1 | KCNH2 50/4885GABRA1 729/4885GABRG2 684/4885 |
| US-20040063760-A1 | Sodium channel modulatiors | SCN1A, SCN2A, SCN1B | KCNH2 89/4885GABRA1 569/4885GABRG2 519/4885 |
| US-20030065013-A1 | Sodium channel modulators | SCN10A, SCN5A, SCN1A | KCNH2 83/4885GABRA1 456/4885GABRG2 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.